Pfizer and BioNTech Agree to Vaccine Technology Transfer with South Africa's Biovac Institute
As reported by Reuters* on Wednesday (
e"), Pfizer and BioNTech, manufacturers and developers of an mRNA-based vaccine against SARS-CoV-2, have agreed to help the South African drug maker Biovac Institute produce about 100 million doses per year of its vaccine, specifically to be targeted to African nations.
As described by the Reuters article, Biovac Institute is "a joint venture between the South African government and private sector partners"; it has an advantage as being the first company in Africa to use mRNA technology to make the vaccine. The scope of the cooperative agreement is limited to "fill and finish" aspects of the vaccine, leaving Pfizer and BioNTech to produce the mRNA components of the vaccine in Europe (for a more detailed description of the vaccine making process,
Impf-Ungerechtigkeit: Die lange Bank der Patentfreigabe (nd aktuell) neues-deutschland.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from neues-deutschland.de Daily Mail and Mail on Sunday newspapers.